Treatment of chronic hepatitis C in drug-naïve patients
|
|
|
- Randell Fox
- 5 years ago
- Views:
Transcription
1 Treatment of chronic hepatitis C in drug-naïve patients 8th International Workshop on HIV & Hepatitis Co-infection Madrid, 31. May 2012 Christoph Sarrazin J. W. Goethe-University Hospital Medizinische Klinik I Frankfurt am Main, Germany
2 Hepatitis C: New treatment era with approval of NS3 protease-inhibitors HCV NS3 Protease-Inhibitor Boceprevir Triple-Therapy HCV Genotype 1 HCV NS3 Protease-Inhibitor Telaprevir Triple-Therapy HCV Genotype 1 EMA Market Authorisation European Union EMA Market Authorisation European Union
3 Triple-Therapies: Improved SVR rates Treatment-naïve Genotype 1 pts. ADVANCE RGT, TVR 12 vs. 8 wks SPRINT-2 Lead-in(LI), RGT vs. non-rgt Sustained virologic response % 69% 0 Response guided TVR 12 wks + PEG2a + Riba Response guided TVR 8 wks + PEG2a + Riba 44% PEG2a + Riba (48 wks) % 66% Response guided LI BOC + PEG2b + Riba 38% TVR TVR SOC BOC BOC SOC LI BOC + PEG2b + Riba (48 wks) PEG2b + Riba (48 wks) Jacobson et al. NEJM 2011 Poordad et al. NEJM 2011
4 Sustained virologic response Triple-Therapies: Improved SVR rates Treatment-experienced Genotype 1 pts. REALIZE (+/- Lead-in) TVR 12 wks + PEG2a + Riba 48 weeks 86% 24% TVR SOC REL 57% 15% TVR SOC P-NR 31% NULL 5% TVR SOC RESPOND-2/PROVIDE* Lead-in (+/-RGT) BOC + PEG2b + Riba 36 / 48 weeks 0 75% 29% BOC SOC REL 52% P-NR 7% BOC SOC 36%* NULL Relapser (REL): negative at end-of-treatment but relapse thereafter Partial Non-Responder (P-NR): 2log wk12 but pos HCV RNA wk 24 Null-Responder (NULL): <2log wk 12 Zeuzem et al., NEJM 2011 Bacon et al., NEJM 2011 *PROVIDE study, Vierling et al., AASLD 2011
5 Antiviral activities of Telaprevir / Boceprevir in other HCV genotypes Mean maximum log10 HCV RNA decline during mono-therapies 7-14 days HCV RNA log10 decline ,4 2,1 3,9 1,4 1,7 0,5 0,9 GT 1 GT 2 GT 3 GT 4 GT 5 GT 6 Telaprevr 750mg TID; Reesink et al., Gastro 2006, Foster et al., Gastro 2011, Benhamou et al., EASL 2009 Boceprevir 400mg TID (current dose 800mg TID); Sarrazin et al., Gastroenterology 2007; Silva et al., APASL 2011 no data
6 Triple-Therapies: HIV co-infection Limited efficacy and long duration of PEG/R Characteristic APRICOT 1 ACTG RIBAVIC 3 Barcelona 4 Number enrolled PEG-IFN 2a 2a 2b 2b RBV 800mg 600mg up to 1g 800mg 800mg up to 1.2g HIV and CD4 status >200/mm 3 or /mm 3 if HIV-RNA <5,000 copies/ml >100/mm 3 + HIV-RNA <10,000 copies/ml or >300/mm 3, tx naïve + not starting ART during trial >200/mm 3 >250/mm 3 and HIV-RNA <10,000 copies/ml ALT elevated NA NA >1.5 ULN Genotype 1, % Bridging fibrosis or cirrhosis, % (cirrhosis) SVR, n/n (%) Genotype 1 51/176 (29) 7/51 (14) 21/123 (17)* 22/59 (38)* *Genotype 1 or 4 IFN: interferon; RBV: ribavirin; ALT: alanine aminotransferase ULN: upper limit of normal; SVR: sustained virologic response 1.Torriani FJ, et al. N Engl J Med 2004;351: Chung RT, et al. N Engl J Med 2004;351: Carrat F, et al. JAMA 2004;292: Laguno M, et al. AIDS 2004;18:F27 36
7 Triple-Therapies: HIV co-infection Potential of DDIs with Telaprevir/Boceprevir Telaprevir Boceprevir RTV 1,2 TVR RTV BOC Peg-IFN 2 n/a BOC EFV 2,3 TVR EFV BOC EFV TDF 2,3 TVR TDF BOC TDF ATV/r 3 TVR ATV n/a DRV/r 3 TVR DRV n/a FPV/r 3 TVR FPV n/a LPV/r 3 TVR LPV n/a Methadone 4 TVR R-methadone ( free fraction) n/a Cyclosporine 5 TVR cyclosporine n/a Tacrolimus 5 TVR tacrolimus n/a Midazolam 2 n/a MDZ Diflunisal 2 n/a BOC Clarithromycin 2 n/a BOC Ketoconazole 2,6 TVR KET BOC Oral contraceptives 2,6 EE NOR DRSP EE Renal impairment 7 TVR n/a 1. Garg V, et al. CROI Abstract 629; 2. Kassera C, et al. CROI Abstract 118; 3. van Heeswijk R, et al. CROI Abstract van Heeswijk R, et al. J Hepatol 2011;54(Suppl. 1): S491; 5. Garg V, et al. ATC Abstract 65; 6. Telaprevir French cohort ATU Protocol. Available at 7. van Heeswijk R, et al. J Hepatol 2011;54(Suppl. 1): S492
8 Triple-Therapies: HIV co-infection Telaprevir Triple-Therapy Study Part A: no ART SVR12 T/PR TVR + PR PR Follow-up 1:1 PR48 (control) Pbo + PR PR SVR12 Follow-up SVR SVR Part B: ART (EFV/TDF/FTC or ATV/r + TDF + FTC or 3TC) SVR12 T/PR TVR + PR PR Follow-up 2:1 PR48 (control) Pbo + PR PR SVR12 Follow-up SVR SVR Weeks (EFV)=efavirenz; (TDF)=tenofovir; (FTC)=emtricitabine; (ATV/r)=ritonavir-boosted atazanavir; (3TC)=lamivudine; (T) TVR=telaprevir 750 mg q8h or 1125 mg q8h (with EFV); Pbo=Placebo; (P) Peg-IFN=pegylated interferon alfa-2a (40 kd) 180 µg/wk; (R) RBV=ribavirin 800 mg/day or weight-based (1000 mg/day if weight <75 kg, 1200 mg/day for if weight 75 kg; France, Germany, n=5 patients) Roche COBAS TaqMan HCV test v2.0, LLOQ of 25 IU/mL, LOD of <10 IU/mL Dieterich et al., CROI 2012
9 Triple-Therapies: HIV co-infection Telaprevir Triple-Therapy Study 100 Patients with SVR (%) n/n = 5/7 11/16 12/15 28/38 T/PR 2/6 4/8 4/8 10/22 PR No ART EFV/TDF/FTC ATV/r/TDF/FTC Total *Patient was defined as SVR12 if HCV RNA was < LLOQ in the visit window Dieterich et al., CROI 2012
10 Triple-Therapies: HIV co-infection Boceprevir Triple-Therapy Mallolas et al., EASL 2012
11 Triple-Therapies: HIV co-infection Boceprevir Triple-Therapy Mallolas et al., EASL 2012
12 Triple-Therapies: HIV co-infection Boceprevir Triple-Therapy Mallolas et al., EASL 2012
13 Telaprevir / Boceprevir Triple-Therapies Adverse events % of patients (Phase II / III-studies) Telaprevir/PR N = Placebo/PR N = 764 Discont. Telaprevir / Placebo due to AEs 14 4 Pruritus Rash Nausea Diarrhea Anorectal symptoms 26 6 Anemia % of patients (Phase III-studies) Boceprevir/PR N = Placebo/PR N = 443 Discont. entire treatment due to AEs Anemia Dysgeusia Neutropenia (500 to < 750/mm 3 ) Dry skin 21 8 Bacon et al. NEJM 2011, Poordad et al. NEJM 2011, Jacobson et al. NEJM 2011, Zeuzem et al. NEJM 2011, Sherman et al. NEJM 2011
14 Triple-Therapy Predictors of response Predictors for lower SVR Non-Response PEG-IFN / Ribavirin pre-treatment Non-CC IL28B-Genotype (rs ) High HCV-RNA baseline level (> 8 x 10 5 IU/ml) Advanced Fibrosis (F3 / F4) Low LDL HCV-Subtype 1a (approx. 10% lower SVR rate) Importance for treatment algorithm in mono-infected pts. Poordad et al. NEJM 2011 Zeuzem et al. NEJM 2011 Bacon et al. NEJM 2011 Berg et al., AASLD 2011 Jacobson et al. NEJM 2011
15 IL28B (rs ) Correlation with SVR / Importance for treatment algorithm? Therapy Tx naive (RGT-arms) Tx experienced (48 weeks) Boceprevir (SVR) Telaprevir (SVR) PEG/R (SVR) CC 82% 90% 64 78% CT/TT 62% 72% 25 27% CC 77% 79% 29 46% CT/TT 73% 61% 15 26% Treatment-naive pts. without cirrhosis: Shortening of Triple-Therapy in patients with IL28B CC-genotype? Poordad et al. EASL 2011, Pol et al. EASL 2011
16 Telaprevir Phase 2 Study (PROVE2) SVR Rates SVR rate PR48 (n=82) Placebo + Peg-IFN + RBV Peg-IFN + RBV 46% T12PR24 (n=81) TVR + Peg-IFN + RBV Peg-IFN + RBV 69% T12PR12 (n=82) TVR + Peg-IFN + RBV 60% T12P12 (n=78) (no RBV) TVR + Peg-IFN 36% Weeks Hézode C, et al. N Engl J Med 2009;360:
17 Telaprevir Phase 2 Study (PROVE2) SVR Rates SVR rate PR48 (n=82) Placebo + Peg-IFN + RBV Peg-IFN + RBV 46% T12PR24 (n=81) TVR + Peg-IFN + RBV Peg-IFN + RBV 69% T12PR12 (n=82) TVR + Peg-IFN + RBV 60% T12P12 (n=78) (no RBV) TVR + Peg-IFN 36% Weeks The IL28B genotype (rs ) was determined in specimens at the PROVE2 French sites Bronowicki et al, EASL 2012, poster (1094)
18 Short treatment in IL28B CC patients SVR rate PR48 (n=82) Placebo + Peg-IFN + RBV Peg-IFN + RBV 46% T12PR24 (n=81) TVR + Peg-IFN + RBV Peg-IFN + RBV 69% T12PR12 (n=82) TVR + Peg-IFN + RBV SVR: 100% for 12/12 patients with IL28B CC 2 T12P12 (n=78) (no RBV) TVR + Peg-IFN 36% Weeks Prospective ongoing study (CONCISE) for 12 weeks triple therapy with TVR BID in treatment naïve genotype 1, CC patients Bronowicki et al, EASL 2012, poster (1094)
19 Triple Therapy New response definitions Abbreviation Meaning Comment SVR Sustained virologic response HCV-RNA undetectable 24 weeks after end of treatment Relapse Partial Non- Response Relapse after end of treatment Week 12 2 log-decline of HCV-RNA but HCV RNA detectable at week 24 Null-Response < 2 log-decline of HCV-RNA at week 12 RVR rapid virologic response HCV-RNA negative at week 4 ervr (TVR) extended RVR Telaprevir HCV-RNA negative at week 4 and 12 ervr (BOC) extended RVR Boceprevir HCV-RNA negative at week 8 and 24 Breakthrough Virologic breakthorough HCV-RNA positive after undetectability or increase of > 1 log step
20 Treatment algorithms for HCV mono-infected patients: Lead-in Boceprevir Telaprevir TW0 TW4 TW8 TW24 TW28 TW36 TW48 TW0 TW4 TW12 TW24 TW48 Naive 4W LI 4W LI 24W BOC 32W BOC 12W PR Naive Relapser 12W TVR 12W TVR +/- 12W PR 36W PR Part.Resp. Relapser 4W LI 32W BOC 12W PR Part.Resp. Null Resp. 12W TVR 36W PR Null Resp. F4 Fibrosis 4W LI 44W BOC F4 Fibrosis 12W TVR 36W PR = undetectable HCV RNA
21 Lead-in versus no Lead-in Individual decision Tolerability of PEG-IFN / Ribavirin alone during Lead-in Adherence on PEG-IFN / Ribavirin alone during Lead-in Individual decision on further treatment Treatment-naive patient with RVR during Lead-in and possibility of 24 weeks PEG/Riba Treatment experienced patient with Null- Response, F4 and < 1 log-decline during Lead-in
22 TVR/BOC sparing treatment RVR during lead-in with PEG/Riba Rates of RVR (HCV RNA undetectable / <12-50 IU/ml at week 4) in treatment-naive patients with chronic hepatitis genotype 1 infection and treatment with PEG-IFN / Ribavirin alone range from 12-65% in different studies from the U.S., Europe and Asia Fried et al., J Hepatol 2011, McHutchison et al., NEJM 2009, Ferenci et al., Gastroenterology 2008, Mangia et al., Hepatology 2008, Berg et al., Gastroenterology 2006, Sarrazin et al., Gastroenterology 2011, Sanchez-Tapias et al., Gastroenterology 2006, Bronowicki et al., Gastroenterology 2006, Buti et al., Hepatology 2010, Yu et al., Hepatology 2008, Liu et al., Clin Infect Dis 2008 Response group HCV RNA Baseline negative* at viral load week 4 < IU/ml week IU/ml * HCV RNA undetectable by TMA Assay (<5-10 IU/ml) INDIV-2 Study (genotype 1, treatment-naïve) PEG-Interferon alfa 2b plus Ribavirin ITT population (n=398) PP population Treatment (n=346) duration n (%) SVR (%) n SVR (%) (weeks) (10) 36 (88) (100) 30 7 (2) 6 (86) 6 6 (100) Sarrazin et al. Gastroenterology 2011
23 Boceprevir Stopping rules Boceprevir TW0 TW4 TW12 TW24 TW28 TW36 Naive 4W LI 24W BOC 4W LI 32W BOC 12W PR Part.Resp. Relapser 4W LI 32W BOC 12W PR Null Resp. F4 Fibrosis 4W LI 44W BOC Stopping rules for Boceprevir : HCV RNA > 100 IU/ml at TW12 HCV RNA detectable at TW24
24 Stopping rules Boceprevir Triple Treatment naive: SPRINT-2-Study, n = 734 Entire treatment was discontinued within the study if HCV RNA was detectable at week 24 Retrospective analysis for introduction of early stopping rules Rate of pts. with stop Week 8 Week 12 missed SVR Rate of pts. with stop missed SVR 50 IU/ml 147 (20%) (11%) IU/ml 120 (16%) (9%) 0 < 3 log-decline 34 (5%) 1 34 (5%) 0 Jacobson et al. AASLD 2011
25 Telaprevir Stopping rules Telaprevir TW0 TW4 TW12 TW24 TW48 Naive Relapser 12W TVR 12W TVR +/- 12W PR 36W PR Part.Resp. Null Resp. 12W TVR 36W PR F4 Fibrosis 12W TVR 36W PR Stopping rules for Telaprevir: HCV RNA > 1000 IU/ml at TW4 or TW12 HCV RNA detectable at TW24
26 Stopping rules Telaprevir Triple Treatment-naive: ADVANCE-Study, n = 903 Telaprevir was discontinued within study if HCV-RNA > IU/ml at week 4 and entire treatment was discontinued if < 2 log decline of HCV RNA at week 12 / HCV-RNA positive at week 24 Retrospective analysis for introduction of early stopping rules Week 4 Week 12 Rate of pts. with stop missed SVR Rate of pts. with stop missed SVR 100 but < IU/ml 19 (2%) 5 10 (1%)? IU/ml 15 (2%) 0 9 (1%) 0 Adda et al. HepDart 2011
27 Viral kinetics of triple-therapy 10 8 Treatment naive (n = 15) Treatment experienced (n = 15) HCV-RNA IU/ml HCV-RNA IU/ml Weeks /therapy Weeks /Therapy Adda et al. HepDart 2011
28 Telaprevir / Boceprevir Treatment algorithms Determination of extended rapid virologic response Boceprevir Telaprevir TW0 TW4 TW8 TW24 TW28 TW36 TW48 TW0 TW4 TW12 TW24 TW48 Naive 4W LI 4W LI 24W BOC 32W BOC 12W PR Naive Relapser 12W TVR 12W TVR +/- 12W PR 36W PR Part.Resp. Relapser 4W LI 32W BOC 12W PR Part.Resp. Null Resp. 12W TVR 36W PR Null Resp. F4 Fibrosis 4W LI 44W BOC F4 Fibrosis 12W TVR 36W PR = undetectable HCV RNA
29 Response guided Triple-Therapie Definition of extended RVR Boceprevir & Telaprevir Studies: HPS/Cobas TaqMan Assay Boceprevir ervr HCV RNA undetectable* at week 8 and 24 * Below the limit of detection (approx. 10 IU/ml) Telaprevir ervr HCV RNA undetectable* at week 4 and 12 * Below the limit of detection (approx. 10 IU/ml) Importance of residual viremia? Differences between different HCV RNA assays?
30 Response guided Triple Therapy Definitions of extended RVR HCV RNA concentrations <25 IU/ml are frequently observed during TVR/BOC tripletherapies (52-67% in Phase 3 studies with TVR/BOC until week 4/8) Overall increased probability of treatment failure in patients with residual viremia (<25 IU/ml but detectable HCV RNA) at week 4/8 during Telaprevir / Boceprevir triple-therapies Harrington et al., Hepatology 2011
31 Response guided Triple Therapy Definitions of extended RVR Higher Relapse-Rates in patients with residual viremia (<25 IU/ml) at week 4 / 12 in patients with shortened treatment duration (24 weeks). Study Time Duration SVR Relapse Boceprevir SPRINT-1 Telaprevir 104 / PROVE1/2 <25 IU/ml wk wks 5/13 (38%) 5/10 (50%) 48 wks 9/12 (75%) 0/9 (0%) negative wk wks 53/62 (85%) 4/57 (7%) 48 wks 62/66 (94%) 0/62 (9%) <25 IU/ml wk wks 6/15 (40%) 4/9 (44%) 48 wks 4/7 (57%) 2/6 (33%) negative wk wks 89/120 (74%) 6/88 (7%) 48 wks 49/64 (77%) 0/44 (0%) Harrington et al., Hepatology 2011
32 International commercially available HCV RNA assays 10 8 IU/ml HCV RT artus TM TMA bdna kpcr Versant TM qual. quant. real-time Amplicor TM vs2 TaqMan TM real-time RealTime HCV TM Qiagen (CE) Siemens (CE/FDA für TMA/bDNA) Roche Diagnostics (CE/FDA) Abbott (CE/FDA)
33 Response guided Triple Therapy Differences between assays Samples obtained from the TMC435 PILLAR study (TMC435-C205) o Treatment-naïve patients received once-daily TMC435 in combination with PegIFNα-2a/RBV o 79-86% of TMC435-treated patients were eligible for shortened treatment of 24 weeks, of whom 85-96% achieved SVR24 In PILLAR, HCV RNA was assessed using Roche High-Pure-System/ COBAS TaqMan assay v2 (HPS) A total of 1411 plasma samples with sufficient volume were selected from 290 of 309 TMC435-treated patients, and re-analysed in a blinded fashion with the Abbott RealTime (ART) assay Visit Number of samples Screening 113 Baseline 16 Day 3 28 Week Week Week Week Week Week Week Total 1411 Fevery et al., EASL 2012
34 Differences between HCV RNA Assays Overall HCV RNA quantification N=326 Abbott RealTime (ART), log 10 IU/mL LLOQ HPS (r 2 =0.978) LLOQ ART Roche TaqMan (HPS), log 10 IU/mL *censored values excluded Fevery et al., EASL 2012
35 Differences between HCV RNA Assays HCV RNA undetectability 217/766 (28.3%) Abbott RealTime (ART) 35/584 (6.0%) <12 IU/mL not detected <12 IU/mL detected 12 IU/mL but <25 IU/mL 25 IU/mL Roche TaqMan (HPS) <25 IU/mL not detected <25 IU/mL detected IU/mL /766 (28.3%) samples from different time points with HCV RNA undetectable by HPS had detectable/quantifiable HCV RNA by ART 35/584 (6.0%) samples undetectable by ART had detectable/quantifiable HCV RNA by RCT For both assays, the majority of these discrepant samples had HCV RNA levels <25 IU/mL Fevery et al., EASL 2012
36 Differences between HCV RNA Assays Assessment of rapid virologic response Proportion of patients, % % <25 IU/mL undetectable 75,5 Not detected 16,5 <25 IU/mL detected 8,0 25 IU/mL Proportion of patients, % % <12 IU/mL undetectable 49,4 Not detected 79.7% <12 IU/mL 30,3 <12 IU/mL detected 7,7 12 and <25 IU/mL 12,6 25 IU/mL Roche TaqMan (HPS) Abbott RealTime (ART) At Week 4, 197/261 (75.5%) samples were undetectable by HPS whereas 129/261 (49.4%) were undetectable and 79/261 (30.3%) <12 IU/mL detectable by ART, leading to a different determination of RVR in 68/261 (26.1%) of cases Fevery et al., EASL 2012
37 Summary New era with Boceprevir / Telaprevir triple-therapies - significant improvement of SVR rates - genotype 1 only - high efficacy also in HIV co-infected patients - complex management, high pill burden, additional AEs, DDI and limited efficacy in non-responders Response guided therapy according to HCV RNA viral kinetics (stopping rules, ervr) Lead-in may be used for testing tolerability, PI sparing and prediction of non-response to PIs IL28B may be used to tailor treatment in the future Importance of HCV RNA assays
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
Protease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
Treatment of chronic hepatitis C in HIV co-infected patients
Treatment of chronic hepatitis C in HIV co-infected patients Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain The most prevalent chronic viral infections in humans HBV
Clinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.
Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago
Optimal Treatment with Boceprevir. Michael Manns
Optimal Treatment with Boceprevir Michael Manns 6th Paris Hepatitis Conference, 14th January 2013 Acknowledgements Benjamin Maasoumy Optimal Patient Selection Defining the Ideal Candidate Treatment Urgency
Case #1. Case #1. Case #1: Audience vote VS. The Great Debate: When to Treat HCV in our HIV coinfected patients
Case #1 The Great Debate: When to Treat HCV in our HIV coinfected patients Medical Management of AIDS December, 2012 Moderated by George Beatty,MD 35 year old African American man, CD4 + 450, HIV RNA
Virological Tools and Monitoring in the DAA Era
Virological Tools and Monitoring in the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
Treating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
Predictors of Response to Hepatitis C Therapy in the DAA Era. Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid
Predictors of Response to Hepatitis C Therapy in the DAA Era Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid Why Predicting HCV Response? Select candidates for therapy Prioritizing
Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona
Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona rrent HCV Therapy 8% % sustained response 6% 4% 2% % 54-61% 41% 34% 25% 16% 6% IFN 24w IFN 48w Peg
HCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano
SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano Market wheretelaprevir has not yet launched Victrelis is still launching January 29 th 214 Developed
Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors
Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors Eric Lawitz, MD, AGAF, CPI The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science
HIV HCV Co Infection Case: The Agnostic Radiologist
HIV HCV Co Infection Case: The Agnostic Radiologist Douglas T. Dieterich, M.D Professor of Medicine Division of Liver Diseases, Gastroenterology and Infectious Diseases Department of Medicine Mount Sinai
ABCs of Hepatitis C: What s New. The Long-Awaited New Era: Protease Inhibitors for HCV Genotype 1
ABCs of Hepatitis C: What s New ACG Postgraduate Course Washington, DC October 30, 2011 Ira M. Jacobson, M.D. Vincent Astor Professor of Medicine Chief, Division of Gastronterology and Hepatology Medical
New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD
Viral Targets for HCV New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD Sites for development of inhibitors Metalloproteinase Serine protease (trans) Core E E2 NS2 NS3 NS4a/NS4b NS5a/NS5b
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
Personalised Treatment with Telaprevir in Graham R Foster Professor of Hepatology Queen Marys University of London
Personalised Treatment with Telaprevir in 2014 Graham R Foster Professor of Hepatology Queen Marys University of London Telaprevir in 2014 Disclaimers I have received funds from: BI, BMS, Janssen, Novarts,
Interferon-based and interferon-free new treatment options
Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt
Hepatitis C Therapy Falk Symposium September 20, 2008
Hepatitis C Therapy Falk Symposium September 20, 2008 Ira M. Jacobson, MD Vincent Astor Professor of Clinical Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the
CURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
Optimal ltherapy in non 1 genotypes:
Optimal ltherapy in non 1 genotypes: genotype 2 and 3 patients Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S. University of Palermo, Italy craxanto@unipa.it Peg IFN alpha plus ribavirin : SVR rate of >80%
Hepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
Triple therapy with telaprevir or boceprevir: management of side effects
Triple therapy with telaprevir or boceprevir: management of side effects Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
Oral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
ةي : لآا ةرقبلا ةروس
سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a
Treatment of Chronic Hepatitis C in HIV infection
Treatment of Chronic Hepatitis C in HIV infection June 25, 211 Andrew Talal, MD, MPH Associate Professor of Medicine Associate Medical Director Center for the Study of Hepatitis C Weill Cornell Medical
Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Co-infected Patients: A 24-Week Treatment Interim Analysis
Poster LB-8 Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Co-infected Patients: A 24-Week Treatment Interim Analysis KE Sherman 1, JK Rockstroh 2, DT Dieterich 3, V Soriano
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
Highlights of AASLD 2012 CCO Official Conference Coverage of the 2012 Annual Meeting of the American Association for the Study of Liver Diseases
Highlights of AASLD 12 CCO Official Conference Coverage of the 12 Annual Meeting of the American Association for the Study of Liver Diseases November 9-13, 12 Boston, Massachusetts In partnership with
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
Michael Fried, MD University of North Carolina Chapel Hill, NC. Ira Jacobson, MD Weill Cornell Medical College New York, NY
Nezam Afdhal, MD Beth Israel Deaconess Medical Center Boston, MA Kim Brown, MD Henry Ford Hospital Detroit, MI Michael Fried, MD University of North Carolina Chapel Hill, NC Jordan Feld, MD Toronto Western
New developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
Treatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
Efficacy and safety of protease inhibitors for sever hepatitis C recurrence after liver transplantation: a first multicentric experience
Efficacy and safety of protease inhibitors for sever hepatitis C recurrence after liver transplantation: a first multicentric experience A. Coilly, B. Roche, J. Dumortier, D. Botta-Fridlund, V. Leroy,
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C
Treatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT
ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT Mitchell L Shiffman, MD Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
Wilhelminenspital, Vienna, Austria; 5 Queen Mary Hospital, University of London, Barts Health, London, UK; 6
Shortening overall treatment to 12 weeks of simeprevir plus PR in treatment-naïve chronic hepatitis C genotype 1 patients: assessment of baseline and Week 2 on-treatment predictors of SVR T Asselah, 1
Treatment Targets HCV Genotype 1 & PIs Treating HCV G2&3 Future Therapies. Advances in treatment of HCV Dr John F Dillon
Treatment Targets HCV Genotype 1 & PIs Treating HCV G2&3 Future Therapies Advances in treatment of HCV Dr John F Dillon Disclosure slide I have received consulting fees and Honoraria from MSD, Abbott,
Introduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
Antiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
Infection with hepatitis C virus (HCV) is a global health concern,
Advances in the Treatment of Hepatitis C Virus Infection Arun B. Jesudian, MD, Maya Gambarin-Gelwan, MD, and Ira M. Jacobson, MD Dr. Jesudian is a Clinical Fellow, Dr. Gambarin-Gelwan is an Assistant Professor
HIV and Hepatitis C: Advances in Treatment
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and Hepatitis C: Advances in Treatment John Scott, MD, MSc Asst Professor University of Washington Presentation prepared & presented by: John Scott, MD,
New Therapeutic Strategies: Polymerase Inhibitors
New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14 th - 15 th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2
Hepatitis C Virus Treatments: Present and Future
Hepatitis C Virus Treatments: Present and Future Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Boehringer Ingelheim,
Best of AASLD 2010 For IAGH. April 2011 Reza Malekzadeh M.D. AGAF Professor of Medicne DDRC/TUMS
Best of AASLD 2010 For IAGH April 2011 Reza Malekzadeh M.D. AGAF Professor of Medicne DDRC/TUMS DAAs Direct-Acting Antivirals Understanding of HCV life cycle Identification of potential targets of antivirals
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy
10 Need to Know Ques2ons
Cirrhosis/ESLD management 1 Need to Know Ques2ons Marion Peters MD UCSF December 212 1. Once a pa2ent with HCV is imaged to look for cirrhosis and none is found, how omen should I repeat imaging in the
Updates on Current Status of HCV Therapy
Updates on Current Status of HCV Therapy K. Rajender Reddy, MD Professor of Medicine, Professor of Medicine in Surgery, Director of Hepatology and Medical Director of Liver Transplantation University of
Areas of Interest. HCV Epidemiology, Natural History HCV Treatment. HBV Epidemiology and Prevention. Monoinfected Coinfected
CROI 2011 UPDATE Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases Univ. of Cincinnati College of Medicine Areas of Interest HCV Epidemiology, Natural History
Personalizzazione della Cura in Epatologia. Epatite Cronica C: Pazienti con Genotipo 2
Monotematica AISF 213 Personalizzazione della Cura in Epatologia Pisa, 17-19 Ottobre 213 Epatite Cronica C: Pazienti con Genotipo 2 Maria Grazia Rumi U.O. Epatologia, Ospedale San Giuseppe Università degli
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons
INVITED ARTICLE HIV/AIDS Kenneth H. Mayer, Section Editor Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons David L. Thomas,
Transformation of Chronic Hepatitis C Treatment
Transformation of Chronic Hepatitis C Treatment UVHS, Adana, 22 May 2015 Christoph Sarrazin Goethe-University Hospital Frankfurt am Main Germany Epidemiology of HCV Infection Global Global HCV Prevalence
Professor Douglas Dieterich Mount Sinai School of Medicine, New York, USA
17 TH ANNUAL CONFERENCE OF THE BRITISH HIV ASSOCIATION (BHIVA) Professor Douglas Dieterich Mount Sinai School of Medicine,, USA 6-8 April 2011, Bournemouth International Centre 17 TH ANNUAL CONFERENCE
Strategies towards cure of HCV infection: a personalized approach. Heiner Wedemeyer Hannover Medical School Hannover, Germany
Strategies towards cure of HCV infection: a personalized approach Heiner Wedemeyer Hannover Medical School Hannover, Germany 1 Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, Biolex,
Evolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
Current State of Treatment for HCV. Nancy Reau, MD Associate Professor of Medicine University of Chicago
Activity Code FA376 Current State of Treatment for HCV Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives Upon completion of this presentation, learners should be
Latest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
HCV Treatment: Why to Wait
HCV Treatment: Why to Wait Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
Les Inhibiteurs de Protéase du VHC
Les Inhibiteurs de Protéase du VHC Pr Jean-Michel Pawlotsky National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
Treatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
Clinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
Pharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
Bristol-Myers Squibb. HCV Full Development Portfolio Overview. Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013
Bristol-Myers Squibb HCV Full Development Portfolio Overview Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013 1 BMS Agents in Clinical Development: DAAs and INF Lambda Lambda
Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2
Phase 3 Treatment Naïve or Experienced Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2 *ENDURANCE-2: Study Features ENDURANCE-2 Trial Design: Randomized, double-blind, placebo-controlled
TITLE: Re-treatment with Direct Acting Antivirals for Chronic Hepatitis C Genotype 1: Emerging Evidence of Clinical Effectiveness and Safety An Update
TITLE: Re-treatment with Direct Acting Antivirals for Chronic Hepatitis C Genotype 1: Emerging Evidence of Clinical Effectiveness and Safety An Update DATE: 02 January 2015 RESEARCH QUESTION What is the
Current Treatments for HCV
Current Treatments for HCV Mitchell L. Shiffman, MD, FACG Advisory Committee/Board Member: Achillion, Anadys, Boehringer-Ingelheim, BMS, Conatus, Genentech, Gen-Probe, Gilead, Globeimmune, GSK, Janssen,
Program Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
The HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany
: Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained
Pierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine
Pierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine Il sottoscritto dichiara di non aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione
BOCEPREVIR (BOC): EVIDENCE FROM TRIALS
BOCEPREVIR (BOC): EVIDENCE FROM TRIALS ROME, FEBRUARY 22 nd -25 th, 212 Savino Bruno, MD Department of Internal Medicine A.O. Fatebenefratelli e Oftalmico Milan, Italy Savino Bruno, MD Director of InternalMedicine,
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) PegIFN and RBV remain vital components of HCV therapy-- selected presentations from: Program Disclosure This activity has been planned and
Hepatitis C en 2013 Tratar o Esperar? Vicente Soriano Servicio de Enfermedades Infecciosas Hospital Carlos III Madrid
Hepatitis C en 2013 Tratar o Esperar? Vicente Soriano Servicio de Enfermedades Infecciosas Hospital Carlos III Madrid Caveats on hepatitis C therapy decision making We treat persons with a liver. They
Associate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
THE USE OF TRIPLE THERAPY IN SPECIAL POPULATIONS (HIV, OLT)
Massimo Puoti Dept. of Infectious Diseases AO Ospedale Niguarda Cà Granda Milan, Italy THE USE OF TRIPLE THERAPY IN SPECIAL POPULATIONS (HIV, OLT) 14 TH AISF Pre-meeting course: HCV treatment: the new
Antiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
Interferon free therapy Are we getting there? Graham R Foster Queen Marys University of London
Interferon free therapy Are we getting there? Graham R Foster Queen Marys University of London IFN free therapy Disclosures I have received personal and institutional funding from companies that sell drug
Express Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
Treatment with the New Direct Acting Antivirals for Hepatitis C
Treatment with the New Direct Acting Antivirals for Hepatitis C Mary Olson, DNP, ANP-BC Clinical Trials Program Director Weill Cornell Medical College The Center for the Study of Hepatitis C Objectives
Treatment of genotype 4 patient. with cirrhosis. Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble
Treatment of genotype 4 patient with cirrhosis Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble Clinical case 52 year-old patient Intra-venous drug user 1987-1989
Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak) Prepared by: Sophie Woolston, MD and David H. Spach, MD Last Updated: December 29, 2014 OMBITASVIR-PARITAPREVIR-RITONAVIR
Feeling right at home
Feeling right at home Getting to Cure From Cure to Eradication Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto SVR Dramatic Improvements
IFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster
IFN-free for Genotype 1 HCV: the current landscape Prof. Graham R Foster Wonderful new drugs are coming Poordad F, et al. New Engl J Med 2014; online DOI: 10.1056/NEJMoa1402869. 2 The New Drugs Two treatment
Ledipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
Martel-Laferrière V, Brinkley S, Bichoupan K, Posner S, Stivala A, Perumalswami P, Schiano T, Sulkowski M, Dieterich DT, Branch AD
On-treatment and Sustained Virologic Response Rates of Telaprevir-based HCV Treatments Do Not Differ Between HIV/HCV Co-infected and HCV Mono-infected Patients Martel-Laferrière V, Brinkley S, Bichoupan
Current Standards in the Treatment of Chronic Hepatitis C
REVIEW ARTICLE Current Standards in the Treatment of Chronic Hepatitis C Wolf Peter Hofmann, Christoph Sarrazin, Stefan Zeuzem SUMMARY Background: In Germany, 0 000 to 500 000 people are chronically infected
Phase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
Comparison of two HCV-RNA assays assessing early response to simeprevir+pegifn/rbv to select patients suitable to shorten therapy to 12 weeks
Comparison of two HCV-RNA assays assessing early response to simeprevir+pegifn/rbv to select patients suitable to shorten therapy to 12 weeks C Sarrazin, 1 M Buti, 2 C Moreno, 3 M Gschwantler, 4 GR Foster,
Viral Hepatitis and HIV. Norah Terrault, MD, MPH Professor of Medicine Director, Viral Hepatitis Center University of California San Francisco
Viral Hepatitis and HIV Norah Terrault, MD, MPH Professor of Medicine Director, Viral Hepatitis Center University of California San Francisco Faculty Disclosures Grant support - Vertex, Roche, Novartis,
New Treatments for Chronic Hepatitis C. Rafael Esteban Hospital Valle Hebron. Barcelona Spain
New Treatments for Chronic Hepatitis C Rafael Esteban Hospital Valle Hebron. Barcelona Spain The present: a complex treatment with a better SVR Genotype 1 Genotypes 2 and 3 Triple therapy Boceprevir (BOC)
TREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
SYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
Update in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana